The Role of LINC02381 in Modulating Cisplatin Resistance in Ovarian Cancer: A Bioinformatics Approach
,
Abstract
Cisplatin resistance presents a significant challenge in cancer therapy, emphasizing the necessity for identifying new regulatory elements that influence drug response. Recent research has revealed the importance of long noncoding RNAs (lncRNAs) in chemotherapy resistance, with LINC02381 identified as a potential regulatory factor.
Through an in-depth bioinformatics analysis, we investigated the impact of LINC02381 on cisplatin resistance in ovarian cancer across various datasets. By conducting differential expression analysis, survival analysis, gene set enrichment analysis (GSEA), and constructing protein-protein interaction (PPI) networks, we identified key pathways associated with LINC02381 expression.
The results indicated that the altered expression of LINC02381 in patients treated with cisplatin was associated with reduced survival. Functional studies and correlation analyses further demonstrated that this LncRNA influences critical pathways and genes related to apoptosis, efflux, DNA repair, and EMT. Lastly, through an examination of its interactions with microRNA and protein networks, we identified LINC02381 as a ceRNA implicated in cisplatin resistance.
Our findings suggest that LINC02381 may influence cisplatin sensitivity in ovarian cancer and establish a basis for further experimental validation, including molecular assays or in vivo analyses, and suggest the potential therapeutic targeting of LINC02381 to combat chemoresistance.
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
3. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141.
4. Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther. 2019;11(4):97.
5. Peña-Flores JA, Bermúdez M, Ramos-Payán R, Villegas-Mercado CE, Soto-Barreras U, Muela-Campos D, et al. Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma. Front Oncol. 2022;12:965628.
6. Nemati H, Fakhre-Taha M, Javanmard AR, Jahanbakhshi A, Mowla SJ, Soltani BM. LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma. J Neurooncol. 2022;158(1):1–13.
7. Liang J, Zhao Z, Xie Y, Lai D, Okereke IC, Velotta JB, et al. Identification and validation of LINC02381 as a biomarker associated with lymph node metastasis in esophageal squamous cell carcinoma. Translational Cancer Research. 2025;14(1):613-25.
8. Chen X, Zhang Z, Ma Y, Su H, Xie P, Ran J. LINC02381 promoted cell viability and migration via targeting miR-133b in cervical cancer cells. Cancer Manag Res. 2020:3971–9.
9. Wang X, Wu P, Zeng C, Zhu J, Zhou Y, Lu Y, et al. Long intergenic non-protein coding RNA 02381 promotes the proliferation and invasion of ovarian endometrial stromal cells through the miR-27b-3p/CTNNB1 Axis. Genes (Basel). 2022;13(3):433.
10. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–83.
11. Köberle B, Schoch S. Platinum complexes in colorectal cancer and other solid tumors. Cancers (Basel). 2021;13(9):2073.
12. Sun MY, Xu B, Wu QX, Chen WL, Cai S, Zhang H, et al. Cisplatin-resistant gastric cancer cells promote the chemoresistance of cisplatin-sensitive cells via the exosomal RPS3-mediated PI3K-Akt-Cofilin-1 signaling axis. Front Cell Dev Biol. 2021;9:618899.
13. Zhang Y, Ai H, Fan X, Chen S, Wang Y, Liu L. Knockdown of long noncoding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1. Biol Res. 2020;53:14.
14. Li Z, Niu H, Qin Q, Yang S, Wang Q, Yu C, et al. lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer. Mol Ther Nucleic Acids. 2019;17:92–101.
15. Ye P, Feng L, Shi S, Dong C. The mechanisms of lncRNA-mediated multidrug resistance and the clinical application prospects of lncRNAs in breast cancer. Cancers (Basel). 2022;14(9):2101.
16. Du J, Chen F, Chen Z, Zhao W, Wang J, Zhou M. LncRNA LINC01664 promotes cancer resistance through facilitating homologous recombination-mediated DNA repair. DNA Repair (Amst). 2024;143:103770.
17. Zhu Y, Shen Y, Chen R, Li H, Wu Y, Zhang F, et al. KCNQ1OT1 lncRNA affects the proliferation, apoptosis, and chemoresistance of small cell lung cancer cells via the JAK2/STAT3 axis. Ann Transl Med. 2021;9(10):891.
18. Wang ZH, Wang JH, Wang KQ, Zhou Y, Wang J. LncRNA FEZF1-AS1 promoted chemoresistance, autophagy and epithelial-mesenchymal transition (EMT) through regulation of miR-25-3p/ITGB8 axis in prostate cancer. Eur Rev Med Pharmacol Sci. 2020;24(5):2420–30.
19. Liu M, Li H, Li X, Pan B, Zhang J, Pan Y, et al. A novel lncRNA FUAT1/TNS4 axis confers chemoresistance by suppressing reactive oxygen species-mediated apoptosis in gastric cancer. Antioxid Redox Signal. 2024;41(1–3):24–41.
20. Sun Y, Wang X, Bu X. LINC02381 contributes to cell proliferation and hinders cell apoptosis in glioma by transcriptionally enhancing CBX5. Brain Res Bull. 2021;176:121–9.
| Files | ||
| Issue | Vol 24 No 5 (2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| Bioinformatics analysis Chemoresistance Cisplatin LINC02381 Ovarian cancer | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
